UAB 9405 
March 16, 1994 
PAGE - 10 
Exclusion Criteria 
The following circumstances, if present, would classify a patient unacceptable for 
including in this trial: 
4.13 Underlying immunodeficiency disorder or immunodeficiency state. 
4.14 Active autoimmune disorder such as rheumatoid arthritis, systemic lupus 
erythematosis, etc. Diagnosis of altered immune function, including eczema, 
atopic dermatitis or autoimmune disease (autoimmune neutropenia, 
thrombocytopenia or hemolytic anemia; systemic lupus erythematosus, Sjogren 
syndrome or scleroderma; myasthenia gravis; Goodpasture syndrome; Addison’s 
disease, Hashimoto’s thyroiditis or active Graves’ disease). 
4.15 Serious active infection requiring antibiotic therapy or other serious intercurrent 
illness. Patients with inflammatory bowel disease. C rohn’s di sease, ulcerative 
colitis, or active diverticulitis are excluded from study . Patients with active 
infections requiring antibiotic treatment (including chronic suppressive therapy) 
are not eligible until the infection has cleared and the antibiotics have been 
stopped for at least three days. 
4.16 Prior radiation therapy to >50% of nodal groups. 
4.17 Prior splenectomy. 
4.18. Concurrent steroid use. 
4.19 Patients with a history of seizures, encephalitis or multiple sclerosis are not 
eligible. 
4.20 Patients who are pregnant, lactating or if of reproductive age, not using adequate 
contraception. 
4.21 Patients who will be unable or unwilling to comply with the study protocol. 
4.22 Patients who are seropositive for HIV or hepatitis B virus. 
Recombinant DNA Research, Volume 19 
[407] 
